In Focus: Advances in Non-Oral Modalities for the Treatment of Acute Migraine

CME Breakfast Symposium

Sunday, September 10, 2017
6:45 AM – 7:00 AM On-site Check-in and Breakfast Buffet
7:00 AM – 8:00 AM CME Symposium

Vancouver Convention Centre East
East Ballroom C, Convention Level
999 Canada Place
Vancouver, BC, Canada


David W. Dodick, MD (Program Chair)
Department of Neurology
Mayo Clinic
Phoenix, Arizona

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Dartmouth Headache Center
Department of Neurology
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire














Migraine treatment includes both preventive therapy, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks. For acute therapy, the most widely used drugs are NSAIDs and triptans. Routes of triptan administration include oral, intranasal, suppository, subcutaneous, and transdermal iontophoretic, as well as a variety of device-enhanced delivery options. Relatively slow onset of action remains a limitation for these formulations, except for the injectable delivery. Novel routes of delivery, such as intradermal, are in development, holding the promise of rapid absorption into the systemic circulation and, thus, rapid relief. Ultimately, the abundance of delivery options provides more choices to patients with migraine.


Upon completion of this activity, participants will be better able to do the following:

  1. Discuss currently available non-oral treatments for acute migraine and their safety and efficacy
  2. Identify non-oral treatments for acute migraine in late-stage development


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with migraine.


There is no registration fee for attending this symposium. Pre-registration does not guarantee seating. Arrive early—seating is limited!


Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact prior to the live event.


This activity is supported by an independent educational grant from Zosano Pharma Corporation.


Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

You will receive an email confirmation within 1 business day after you complete the registration.

If you are unable to register online or do not receive your confirmation email after registering (don't forget to check your spam email folder), please email

CME Breakfast Symposium
Group visibility: 
Public - accessible to all site users